Sponsors and CROs cannot select a site they have never heard of. Long before a protocol synopsis or a site qualification visit enters the picture, a site either exists inside the channels a sponsor's feasibility team actually searches, or it does not. Getting more studies starts there, not with a sharper pitch.
37%
of enrolled sites under-enroll their own target (Tufts CSDD, site-level data)
39%
meet their target outright, the baseline record a new site is measured against (Tufts CSDD)
Visibility Comes Before the Pitch
A sponsor's feasibility team does not start a study by browsing for new sites to discover. They start from a shortlist: sites already inside a CRO database, sites with a documented track record on ClinicalTrials.gov, sites a recruitment partner has already vetted, sites a colleague mentioned at a conference. A site outside all four of those channels is not being passed over. It simply is not part of the search.
That is a different problem than most sites think they have. "We need to market ourselves better" assumes the constraint is persuasion. For most sites that feel invisible to sponsors, the real constraint is infrastructure: the site has not built the presence that puts it in front of the people running the search in the first place.
That infrastructure is buildable, and it does not require a marketing budget. It requires knowing which channels sponsors actually use, and keeping the record in each one current.
Where Sponsors and CROs Actually Look for Sites
Four channels account for most site discovery before a specific study exists. None of them require a sponsor to already know your site's name.
CRO and sponsor site databases
Most major CROs maintain a site database that feasibility teams query first when a new study needs sites in a given therapeutic area or geography. Registration is free. The mistake most sites make is treating it as a one-time task: fill out the profile at onboarding, then never touch it again while therapeutic experience and enrollment history quietly go stale.
ClinicalTrials.gov as a public track record
Every study a site has run leaves a public trace. A feasibility reviewer checking ClinicalTrials.gov sees which studies a site completed, in what indications, and whether prior listings were closed out cleanly. A clean, current public history reads as active and reliable before a single conversation happens.
Recruitment and site-identification partners
Agencies that identify sites for sponsors and CROs are themselves a channel, not a substitute for the other three. Building a site profile for a sponsor's consideration means looking at the same signals a sponsor's own feasibility team looks at: therapeutic fit, prior enrollment performance, current capacity. A partner relationship adds a parallel path into studies a site would otherwise never see posted anywhere.
Peer referral and site networks
Sites in the same therapeutic area or region refer overflow work to each other constantly, especially when one site is at capacity for a given protocol. This channel runs almost entirely on reputation, which is the same input every other channel is also measuring.
Direct outreach: conferences and medical liaisons
Industry events like ACRP put site staff in the same room as sponsor and CRO decision-makers. Pharmaceutical medical liaisons carry pipeline information most sites never see otherwise. This channel is the slowest to pay off and the easiest to sustain with a standing practice instead of a single trip.
These four channels are largely fixed. What varies, and what actually determines whether any of them produces a study offer, is what a sponsor finds when they look.
The Record That Makes Any Channel Work
A stale database profile costs a site nothing to leave alone, and costs it everything when a feasibility reviewer opens it. The same is true of a ClinicalTrials.gov listing left in "recruiting" status months after a study closed, or a referral conversation with no current enrollment numbers to back it up.
Every site, whether it realizes it or not, is being measured against an industry-wide pattern. Site-level data across roughly 16,000 investigative sites found that 37% under-enroll their assigned target and 39% meet it outright, with the remainder split between sites that enroll zero patients and sites that exceed target (Tufts CSDD). A feasibility team pulling up an unfamiliar site has no way to know which group that site falls into unless the site's own record tells them.
That pattern is not a judgment on any individual site. It is the reality every channel above is filtering through. A specific, current, and honest track record answers the question a general capability statement cannot: not "can this site run a study," but "has this site actually delivered, and on what." Our guide to clinical trial enrollment metrics covers the specific numbers worth tracking and reporting, and our guide to becoming a preferred clinical site covers the checklist the strongest sites already run.
A current, specific record is the credential. A polished sponsor package, and everything else on this list, is secondary to it.
Keeping a Sponsor-Facing Profile Current
A profile does not need to be elaborate to work. It needs to be accurate and recently touched. Four habits keep it that way.
Update database entries on a fixed schedule, not just at onboarding
Quarterly is enough. Put it on a calendar the same way a compliance renewal date would be. An untouched profile reads the same to a feasibility reviewer whether it went stale from neglect or from a genuinely quiet quarter.
List actual numbers, not general capability claims
"Experienced in cardiovascular research" tells a reviewer nothing they can act on. "Enrolled 11 patients across a 26-week Phase 3 T1D protocol" tells them exactly what to expect if they send the next study your way.
Close out ClinicalTrials.gov listings the same week a study ends
A study still marked recruiting six months after the last patient was randomized is one of the easiest things for a reviewer to flag as a site that does not maintain its own records.
Name one person as the owner
Profile maintenance falls through when it is everyone's job and therefore no one's. A single named owner, PI or coordinator, keeps it from going stale when staff turns over.
None of this requires new headcount. It requires deciding that visibility upkeep happens on a schedule instead of during the next study search.
Where a Recruitment Partner Fits
A site can do everything above and still miss studies that never get posted anywhere a site would find on its own. Sponsors and CROs increasingly work through recruitment partners specifically because vetting sites from scratch for every study is slow. A partner that already has sponsor relationships and a track record of its own becomes a channel that surfaces studies a site's own database presence cannot reach alone.
That only works if the partner backs a recommendation with something more than a claim. Sites weighing whether a specific opportunity is worth pursuing can check if a study qualifies for a randomization commitment before any conversation goes further.
Talk through your site's fit with our team.
Book a free consultation to see whether a current sponsor opportunity matches your site's therapeutic experience and capacity. No commitment required.
Book a Free ConsultationPhase 3, vTv Therapeutics T1D
$1,818 CPP
11 randomized patients · $20,000 investment · 3 site locations
Read the case studyPediatric RSV Vaccine, Blue Lake Biotechnology
$3,000 CPP
10 randomized patients · $30,000 investment · 3 site locations
Read the case studyWhat Quietly Costs Sites Consideration
Three patterns show up repeatedly in sites that stay invisible to sponsors, and none of them are about the quality of the site's work.
A profile gets claimed once and then abandoned when the person who set it up changes roles. That is an administrative gap, not a reflection on how the site runs studies, but a feasibility reviewer has no way to tell the difference from outside.
A site holds back on reporting a study where enrollment fell short, worried it will count against them later. The opposite tends to be true: an unexplained gap in the public record reads as more risk than a specific number with context, because the reviewer is left to guess.
Attraction gets treated as a seasonal push: worked hard when a site notices its pipeline thinning, then dropped once a study comes in. The channels above reward a standing practice instead. A profile touched once a year competes against sites that touch theirs every quarter, and the gap compounds.
Visibility Compounds the Same Way a Track Record Does
The sites that keep getting studies are rarely the ones with the most polished sponsor package. They are the ones a feasibility reviewer can find, verify, and trust within a single search, because the database profile, the public record, and the actual numbers all say the same thing.
Most of the work in this guide is a handful of profiles kept current and a track record reported honestly instead of managed around. Sites that treat that as a standing practice show up in more searches than sites that treat it as a project to revisit once a year.
Sources: Tufts Center for the Study of Drug Development (site-level enrollment performance, 151 Phase II/III trials across roughly 16,000 investigative sites, 2008-2010 data, Jan/Feb 2013 Impact Report: 37% under-enroll, 39% meet target); Clinical Enroll (first-party CPP and portfolio data from published case studies, clinicalenroll.com/case-studies).